August 18, 2021Akili Interactive, the developer behind the first FDA-approved game-based prescription treatment for ADHD, announced this week that it is partnering with TALi Digital, an Australian-based digital health company, to license its attention-improving game software in the U.S.
provided FDA approval.Under the deal, the two companies will work together to execute clinical trials of TALi’s video game-based technology — designed to screen for and improve early childhood attention impairments — in pediatric ADHD and pursue FDA regulatory clearance.
Upon securing FDA approval, Akili will lead the treatment’s U.S. commercialization and roll-out.The agreement complements Akili’s own flagship product, EndeavorRx, a game-based digital.
Read more on additudemag.com